Emerging data suggest Retatrutide , a dual activator targeting both GLP-1 and another hormone, appears to offer a significant step forward for obesity loss . Early human investigations have shown substantial losses in body mass , possibly outperforming existing weight-loss medications . Nevertheless , further study is necessary to thoroughly determ